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We have  investigated  the  relationship  between  the 
catecholamine-induced  occurrence  in 132 1N1 human 
astrocytoma cells of &adrenergic receptors that ex- 
hibit  low  apparent affinity for  hydrophilic  ligands in 
short-time assays with  intact cells and a  population  of 
&adrenergic  receptors  that  migrate in a  light vesicle 
fraction on sucrose  density  gradients.  Pretreatment of 
cells with  concanavalin A prevents  the  generation of 
both  of  these  forms  of  the  receptor  during  incubation 
with  agonists but does  not  prevent  the  agonist-induced 
decrease  in  isoproterenol-stimulated  cyclic AMP pro- 
duction  that  also  occurs  during  desensitization. Selec- 
tive labeling  of  the low affinity &receptors  with 
pindolol  followed  by  centrifugation on sucrose  density 
gradients  revealed  that all of  the  receptors  in  the  light 
vesicle fraction  from  desensitized cells were  of  the  low 
affinity type, but that a portion of the low affinity 
receptors  also  migrated  in  a  heavier  sucrose  fraction 
together with the plasma membrane. In contrast, in 
control cells, no low affinity receptors  were  present  in 
the  heavy  sucrose  fractions. The agonist-induced oc- 
currence of these various forms of the /?-adrenergic 
receptor can be explained on the basis of current 
models  of  desensitization i volving agonist-induced  in- 
ternalization of &adrenergic  receptors. 
High affinity binding of agonists to 6-adrenergic receptors 
on intact 1321N1 human astrocytoma cells can be demon- 
strated in short-time (15 s) radioligand-assays (1). During 
further (>1 min) incubation of cells in the presence of agonist, 
approximately half of the cellular 8-adrenergic receptors are 
converted from this high affinity form to a form that exhibits 
low apparent affinity for the agonists isoproterenol and epi- 
nephrine (1, 2). This low apparent affinity results, at least in 
part, from  slow attainment of equilibrium binding of these 
ligands with 8-adrenergic receptors (2). The low apparent 
affinity (slow equilibration) in 1321N1 cells appears to be 
related to  the hydrophilicity of these agonists rather than  to 
the fact that they are agonists, since similar changes in 
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binding are observed for the hydrophilic antagonist sotalol 
but not for the more lipophilic antagonists metoprolol and 
propranolol (2). High affinity binding of agonists and agonist- 
induced  conversion of this high affinity form to  a form exhib- 
iting much  lower affinity has been demonstrated by a number 
of other laboratories using other cell lines (3-5). 
Incubation of cells  with agonists also leads to a change in 
the sedimentation properties of 6-adrenergic receptors mea- 
sured by differential centrifugation (6,7) or by sucrose density 
gradient centrifugation (8, 9). In native 1321N1 astrocytoma 
cells, nearly all of the 8-adrenergic receptors migrate in a 
fraction that contains the enzyme adenylate cyclase and  other 
markers for the plasma membrane (8,9). Following incubation 
with agonist, about half of the cellular @-adrenergic receptors 
are converted to  a form that is recovered in a light vesicle 
fraction at much lower sucrose densities than that of the 
plasma membrane fraction (€49). In analogy with polypeptide 
hormone receptor systems (10, 11), it has been postulated (8, 
9) that  this change in sedimentation properties may result 
from internalization of /%adrenergic receptors within endo- 
cytotic vesicles. 
In a previous report (2), we postulated that  the low apparent 
affinity and slow equilibration of hydrophilic ligands with the 
altered &adrenergic receptors present  in cells preincubated 
with agonists might be explained by receptor internalization, 
and consequently, reduced  accessibility of these receptors to 
ligands that cross cell membranes slowly. In  the experiments 
reported here, we have directly examined the relationship 
between the conversion of 8-adrenergic receptors to  the low 
apparent affinity form and the appearance of @-adrenergic 
receptors in the light vesicle fraction. The results indicate 
that  the two phenomena are closely related and support the 
concept of agonist-induced internalization of &adrenergic 
receptors. 
EXPERIMENTAL PROCEDURES 
obtained from Sigma Chemical Company, ConA’ was from Calbi- 
Materials-(-)-Isoproterenol bitartrate  and (&)-propranolol were 
ochem, and ultrapure sucrose was from Schwarz-Mann. [‘HIAdenine 
and sodium [laI]iodide were obtained from ICN and Amersham, 
respectively. (-)-Pindolo1 was a gift from Sandoz Pharmaceuticals, 
and both nonradioactive and 3H-labeled CGP-12177 were gifts from 
Dr. M. Staehelin (Ciba-Geigy). ‘261-Pindolol  was prepared by a mod- 
ification (12) of the method of Barovsky and Brooker (13). 
The abbreviations are: ConA, concanavalin A; Hepes, N-2-hy- 
droxyethylpiperazine-N’-2-ethanesulfonic acid; Eagle’s-Hepes, 
serum-free Eagle’s  medium containing 20 mM Hepes, pH 7.4;  BARLv 
and BARm, light vesicle and low affinity forms of @-adrenergic 
receptors. 
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Cell Culture-Human astrocytoma cells (1321N1) were grown as 
previously described (1). Cells taken from confluent flasks were 
seeded in  either 35-mm (Falcon) or 150-mm tissue  culture dishes at 
a density of approximately 8OOO cells/cm2 and used on the 4th day 
following subculture. For desensitization, cells were incubated for 20 
min (unless otherwise specified) a t  37  "C in growth medium contain- 
ing 1 p~ isoproterenol plus 1 mM sodium ascorbate, and control cells 
were incubated for 20 min in growth medium with ascorbate alone. 
Cells were then washed two to three times with Eagle's-Hepes at  
37  "C prior to assay. 
Pretreatment of  CeUs with Cod-The medium was aspirated from 
cell sheets  on 35-mm dishes and replaced with Eagle's-Hepes with or 
without 0.25 mg/ml C o d .  The cells were incubated at  37  "C for 30 
min. The cells were then incubated an additional 20 min with 1 p~ 
isoproterenol in 1 mM sodium ascorbate (desensitized) or with ascor- 
bate alone (control) in  the continued presence or absence of C o d .  
The cell sheets were rinsed two to three times with Eagle's-Hepes at  
37  "C prior to assay. 
Competition Binding Assays-Binding to intact cell @-adrenergic 
receptors in  the absence or presence of varying concentrations of 
isoproterenol or CGP-12177 was measured in 15-s assays with 100 
PM '261-pindolol as previously described (1,2). Specific binding in  the 
absence of competing ligand was approximately 1500 cpm bound/ 
assay. Nonspecific binding, measured in each experiment as that 
occurring in the presence of 1 p~ propranolol, was about  15% of total 
binding. 
Competition curves were analyzed by computerized nonlinear least- 
squares curve fitting of the raw data to models for law  of mass action 
interaction of the competing ligand with a single site or with two 
independent sites as described previously (1, 2). Data  are expressed 
as  the percentage of '%I-pindolol specifically bound in the absence of 
competitor. Standard errors of all  points  on the curves were generally 
less than 5% of the amount specifically bound in the absence of 
competitor. It should be noted that these  short-time binding assays 
provide an estimate of the true affinity for the receptor only for 
competing ligands that attain equilibrium with the receptor very 
rapidly (1, 14). 
Cyclic AMP Accumulation in Intact Cells-Washed cells were in- 
cubated for 1 min at  37 "C in Eagle's-Hepes containing [3H]adenine 
(5 pCi/ml) and either 10 pM isoproterenol in 1 mM ascorbate or 
ascorbate alone. This medium was then aspirated and 1 ml of 5% 
trichloroacetic acid was added. ['HICAMP was measured as previously 
described (2). 
Prelubeling of  CeUs and Sucrose Density Gradient Centrifugatwn- 
Cells  grown on 150-mm dishes were incubated for 2,5, or 20 min in 
growth medium with 1 p~ isoproterenol plus ascorbate (desensitized) 
or ascorbate alone (control) and  then rapidly washed three times with 
10 ml of Eagle's-Hepes at  37 "C prior to labeling. Cells were then 
incubated for 15 s with 10 ml of 100 PM '%I-pindolol in the absence 
or presence of various competing ligands. This medium was aspirated 
and  the cells were washed three times at 37 "C with 10 ml  of Eagle's- 
Hepes containing 100 PM propranolol. The dishes were then treated 
on ice for 5 min with 10 ml of ice-cold Eagle's-Hepes containing 0.25 
mg/ml of ConA. This was followed  by rinsing with 10 ml of ice-cold 
lysis buffer (1 mM Tris, pH 7.4,2 mM EDTA) and a 20-min incubation 
with lysis buffer on ice. The lysis buffer was aspirated and  the cells 
were lysed by scraping with a rubber policeman. 
Sucrose density  gradients were formed using an ISCO  model  570 
gradient former at 4 "C. Gradients consisted of a 1.2-ml cushion of 
5% sucrose on top of a 9-ml linear gradient from 30 to 60% sucrose. 
The lysates from three dishes were combined (2-3 ml) and applied to 
each gradient. Centrifugation was for 60 min at 35,000 rpm (217,000 
X g-) in a Beckman SW 40 Ti rotor and a Beckman L8-70 refrig- 
erated ultracentrifuge at  4 "C. Fractions of 0.6 ml  were collected from 
the top of each gradient with an ISCO model 568 fractionator. The 
amount of '"I-pindolol in each fraction was then determined in a y 
counter. All of the 1261-pindolol recovered from the gradient was 
apparently &adrenergic receptor-associated radioactivity, since when 
labeling was carried out in the presence of 1 p~ propranolol, radio- 
activity was only recovered in the  supernatant fractions. 
In one experiment, treatment of cells, centrifugation, and fraction- 
ation were performed as above, except that  the labeling was on ice 
for 6 h with [3H]CGP-12177 and  the subsequent washes were with 
ice-cold Eagle's-Hepes containing 100 p~ propranolol. The radioac- 
tivity present  in each fraction was then determined by liquid scintil- 
lation counting. 
Treatment of Gradient Fractions with a-Methylmnwsde- 
Plasma membrane fractions from a sucrose density gradient centrif- 
ugation as described above were pooled, diluted Sfold with lysis 
buffer, and centrifuged for 20 min at 18,000 rpm (37,000 X g) in a 
Beckman JA-21 rotor and a Beckman 5-21 refrigerated centrifuge at  
4 "C. The pellet was resuspended in 0.5 M a-methylmannoside in 10 
mM Tris, pH 7.4, and incubated for 10 min at  37 "C. The sample was 
then cooled and centrifuged on a second sucrose density gradient in 
a manner identical to the first centrifugation. This gradient was 
fractionated and the amount of '261-pindolol in each fraction was 
determined. 
RESULTS 
Effects of C o d  Pretreatment-Preincubation of 1321N1 
cells with ConA has been  shown to block the agonist-induced 
shift of receptors from the plasma membrane to light vesicle 
fractions (9). However, the agonist-induced decrease in iso- 
proterenol-stimulated adenylate cyclase activity as measured 
in broken cell preparations was not prevented by preincuba- 
tion of cells with ConA (9). These results indicated that  the 
"uncoupling" of &adrenergic receptors from stimulation of 
adenylate cyclase is a separate event from conversion of 
receptors to the light vesicle  form. To determine the relation- 
ship between the conversion of receptors to the low affinity 
form and these other aspects of desensitization, the effect of 
ConA on &adrenergic receptors and adenylate cyclase activity 
in  intact cells was studied? 
High affinity binding of isoproterenol was observed in 
short-time assays with control cells pretreated for 30 min with 
0.25 mg/ml ConA (Fig. 1). The amount of lZ6I-pindolol bound 
in the absence of competing ligand was the same in cells 
pretreated with ConA as  in cells pretreated with buffer alone 
(Table I); thus,  the  treatment with ConA did not  alter acces- 
sibility of the receptor to  the antagonist '2SI-pindolol. Pre- 
treatment with ConA also did not alter  the binding of isopro- 
terenol to  the receptor in control cells as measured in short- 
time binding assays. Computer analysis of the isoproterenol 
competition curve  from control cells  (Fig. 1) indicated that 86 
f 3% of '261-pindolol binding was inhibited with an ICw of 83 
nM and  the remaining 14% was inhibited with an IC, of 180 
p ~ ;  these results are essentially the same as those obtained 
previously in cells not pretreated with ConA (1,2). 
When cells that had not been treated with ConA were 
preincubated for 20 min with isoproterenol, approximately 
50% of the 8-adrenergic receptors were converted from the 
high affinity form to  the low affinity form (Fig. 1, Table I, 
and Ref. 2). In contrast, when cells pretieated with ConA 
were  exposed to isoproterenol, there was  only a slight increase 
in @-adrenergic receptors in the low affinity form  (Fig. 1 and 
Table I). In addition, there appeared to be an approximately 
2-fold increase in the IC,, at the high affinity site. Computer 
analysis of the curve for isoproterenol-pretreated cells in Fig. 
1 indicated that 76% of '=I-pindolol binding was inhibited 
with an 1C60  of 160 f 35 nM and 24% with an ICSO of 730 PM. 
This use of ConA should be distinguished from the routine use of 
ConA in experiments involving sucrose density gradient centrifuga- 
tion. In the experiment depicted in Fig. l and Tables I and 11, ConA 
pretreatment was carried out prwr to the induction of desensitization 
by isoproterenol at 37  "C. This use of ConA is based on our previous 
report  demonstrating that ConA  blocks the catecholamine-induced 
change in the membrane form of &adrenergic receptors (9). However, 
in all experiments involving sucrose density gradient centrifugation, 
e.g. Figs. 2,4,5,6,  and 7,  ConA treatment of the cells was carried out 
on ice subsequent to any incubation of the cells with isoproterenol, 
CGP-12177, and/or 1261-pindolol and  just prior to hypotonic lysis of 
the cells and sucrose density gradient centrifugation. This use is 
based on the more effective separation of light vesicle and plasma 
membrane @-adrenergic receptors following ConA treatment (8, 9, 
20). 
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FIG. 1. Effect of ConA on the isoproterenol-induced for- 
mation of a low affinity form of &adrenergic receptors. Cells 
were incubated for 30 min in the absence (W) or presence (0, 0) of 
0.25 mg/ml ConA, and then for an additional 20 min with 1 PM 
isoproterenol ({SO) plus ascorbate (m), isoproterenol plus ascorbate 
and 0.25 mg/ml ConA (O), or ascorbate alone and 0.25 mg/ml  ConA 
(0). The cells were washed and binding of ‘261-pindolol (PIN)  was 
determined in  the presence of the indicated concentrations of isopro- 
terenol in 15-s assays as described under “Experimental Procedures.” 
The experimental points shown are the average of three experiments 
performed in duplicate. 
TABLE I 
Effects of pretreatment  of cells with C o d  on ligand binding  to @- 
adrenergic  receptors 
1321N1 cells were pretreated (30 min) in the absence or presence 
of  0.25 mg/ml ConA and  then in the absence or presence (20 min) of 
1 PM isoproterenol as described under “Experimental Procedures.” 
The cells were then washed and incubated with 100 pM ‘251-pindolol 




incubation incubation Presence of 
Low 
apparent 
10 pM Absence of affinity 
isopmkrenol  isoProkreno1 
cpm % 
-ConA -Isoproterenol 252  1614  16 
-ConA +Isoproterenol 969  1615  60 
+ConA -Isoproterenol 248  1626 15 
+ConA +IsoDroterenol 352 1568 23 
TABLE I1 
Effects of pretreatment of cells with ConA on cyclic AMP 
accumulation 
1321N1 cells were treated with ConA and isoproterenol as described 
in Fig. 1. The cells were then washed and [3H]cAMP accumulation 
was measured as described under “Experimental Procedures.” 
30-min 20-min 
[3H]cAMP formed D~~~~~~~ 




-ConA -IS0 189 2130 
-ConA +IS0 231  954 55 
+ConA -IS0 187 1911 
+ConA +IS0 282  1059 45 
Although ConA almost completely blocked the agonist- 
induced conversion of receptors to  the low affinity form, it 
had only a minimal effect on the agonist-induced loss of 
isoproterenol-stimulated cyclic AMP accumulation. A 20-min 
exposure to agonist caused a comparable decrease in isopro- 
terenol-stimulated cyclic AMP accumulation in  both control 
and ConA-pretreated cells (Table 11). Pretreatment with 
ConA did not cause a change in the basal level of cyclic AMP 
accumulation in control or desensitized cells, but did cause a 
small decrease in the level of isoproterenol-stimulated cyclic 
AMP accumulation in  control cells.  However, the major effect 
of  ConA apparently is not on the interaction of isoproterenol 
with p-adrenergic receptors or on the coupling of p-adrenergic 
receptors to adenylate cyclase but rather is on the subsequent 
conversion of the receptors to  the low affinity form. 
Distribution of Low Affinity  Receptors on Sucrose Density 
Gradients-The relationship between @-adrenergic receptors 
exhibiting high and low apparent affinity for isoproterenol in 
short-time assays with intact cells and those migrating in the 
plasma membrane and light vesicle fractions on sucrose den- 
sity gradients was assessed directly. Control and desensitized 
cells were labeled with 1251-pindolol for 15 s iR the absence or 
presence of 1 pM propranolol or 10 pM isoproterenol. Pro- 
pranolol at  1 p~ blocks binding of ‘251-pindolol to all p- 
adrenergic receptors, whereas 10 p~ isoproterenol selectively 
blocks binding of ‘251-pindolol to  the high affinity receptors 
without blocking binding to  the low affinity receptors (see 
Fig. 1 and Ref. 2). The cells were then washed at 37 “C to 
remove  ‘251-pindolol not bound to 6-adrenergic receptors, 
treated with ConA, lysed, and subjected to sucrose density 
gradient centrifugation. The small amount of ‘251-pindolol 
bound in the presence of 1 p~ propranolol (nonspecific bind- 
ing) did not enter the sucrose gradient and, thus, did not 
interfere with quantitation of labeling of receptors in  the light 
vesicle and plasma membrane fractions. 
When  control cells were labeled in the absence of isopro- 
terenol, the bulk of bound 1251-pindolol migrated in the plasma 
membrane fraction with only a small amount migrating in 
the light vesicle fraction (Fig. 2B). The presence of 10 p~ 
isoproterenol during the ‘251-pindolol-labeling step essentially 
completely blocked labeling of receptors in the plasma mem- 
brane  fraction; some labeling of the light vesicle fraction  still 
occurred (Fig. 2B). Thus,  in control cells, all of the labeled p- 
adrenergic receptors in the plasma membrane fraction  exhibit 
high affinity for isoproterenol, whereas a population of recep- 
tors  exhibiting low affinity for isoproterenol can be identified 
in the light vesicle fraction. 
When desensitized cells were labeled in the absence of 
isoproterenol, bound ‘251-pindolol was distributed approxi- 
mately equally between the plasma membrane and light ves- 
icle fractions (Fig. 2.4). These  results,  obtained by labeling of 
p-adrenergic receptors on intact cells prior to gradient cen- 
trifugation,  are similar to those  obtained  in previous studies 
(8, 9) employing membrane-binding assays of p-adrenergic 
receptor distribution  after gradient centrifugation. The pres- 
ence of 10 p~ isoproterenol during the ‘251-pindolol labeling 
did not decrease binding to p-adrenergic receptors in  the light 
vesicle fraction; indeed, in some experiments, the amount of 
labeling actually increased (Fig. 2 A ) .  In  contrast  to  the com- 
plete inhibition of labeling of the plasma membrane receptors 
in control cells, ‘Z51-pindolol binding to @-adrenergic receptors 
in the plasma membrane fraction of desensitized cells was 
only partially blocked by 10 p~ isoproterenol. Thus,  in desen- 
sitized cells, all of the receptors in the light vesicle fraction 
exhibit low apparent affinity for isoproterenol, whereas the 
plasma membrane fraction  contained  both igh and low affin- 
ity receptors. 
Studies with CGP-12177-The recently developed p-adre- 
nergic receptor ligand CGP-12177 is an antagonist that  has 
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FIG. 2. Selective labeling  of affinity forms  of  the @-adre- 
nergic  receptor revealed by sucrose  density  gradient centrif- 
ugation. Control (CTL) and desensitized (DESENS) cells were 
washed  and labeled for  15 s with '251-pindolol (PZN) in the absence 
(0) or presence (0) of 10 pM isoproterenol (ZSO). After  washing to 
remove '261-pindolol not bound to @-adrenergic receptors, the cells 
were treated with ConA and lysed, and the lysates were  centrifuged 
on sucrose density gradients as described  under  "Experimental  Pro- 
cedures." The results shown are from a single experiment; similar 
results were obtained in four additional experiments. 
been reported to bind only to receptors on the surface of intact 
cells (15). This ligand, like isoproterenol, epinephrine, and 
sotalol (2), competed with high apparent affinity for only 
about 84% of the '261-pindolol-binding sites in short-time 
assays with control cells  (Fig. 3). In desensitized cells, only 
about 27% of the '251-pindolol binding was inhibited with high 
affinity by CGP-12177 (Fig. 3). Further inhibition of "'1- 
pindolol binding under these short-time assay conditions was 
not seen at  concentrations of CGP-12177 as high as 100 p~ 
in either control or desensitized cells. It should be noted that 
the  apparent affinity of @-adrenergic receptors for CGP-12177 
under these assay conditions (30-50 nM) is much  lower than 
the true affinity (0.15 nM) measured in equilibrium assays 
(Fig. 3). The high affinity of this ligand would  be expected to 
result in slow equilibration even with those receptors exposed 
on the cell surface and  thus readily accessible to CGP-12177. 
The distribution of high and low affinity binding sites for 
CGP-12177 between the plasma membrane and light vesicle 
fractions on sucrose density gradients was determined as 
described above for isoproterenol, with 10 p~ CGP-12177 
chosen as a concentration to block  high affinity sites without 
altering binding to low affinity sites. The results obtained 
(Fig. 4) were  completely analogous to those obtained with 10 
pM isoproterenol (Fig. 2). In control cells, 10 pM CGP-12177 
- 
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FIG. 3. Effect of CGP-12177 on  the  binding  of  '261-pindolol 
to intact  control  or  desensitized 1321N1 cells. Control (0) or 
desensitized (20 min; 0) cells were  incubated  for  15 s (0, 0) in the 
presence  of  100 PM '261-pindolol (PZN) and the indicated concentra- 
tions of CGP-12177. Alternatively, naive cells were incubated  for 60 
min in the presence of the indicated concentrations of  CGP-12177 
prior to performing 15-s assays of '261-pindolol  binding in the presence 
of the indicated concentrations of CGP-12177 (A). The experimental 
points shown are  from one (A) or two (0,O) experiments performed 
in duplicate. 
blocked labeling of receptors in the plasma membrane fraction 
with minimal effect on labeling of light vesicle receptors. In 
desensitized cells, 10 p~ CGP-12177 did not inhibit labeling 
of light vesicle receptors, and labeling in the plasma mem- 
brane fraction was  only partially blocked. 
Previous studies in other cell lines have used 13H]CGP- 
12177 binding on ice to selectively  label receptors exhibiting 
high affinity (rapid accessibility) for this ligand on intact 
cells. This fraction of ,&adrenergic receptors presumably rep- 
resents cell surface receptors (15-18). When such an experi- 
ment was performed with 1321N1 cells (Fig. 5), selective 
labeling of P-adrenergic receptors in the plasma membrane 
fraction occurred in both control and desensitized cells. As 
expected, there were  fewer labeled P-adrenergic receptors in 
the plasma membrane fraction from desensitized cells. No 
labeling of ,&adrenergic receptors in the light vesicle fraction 
of control or desensitized cells  was detected. 
Evidence against Lysosomal p-Adrenergic Receptors-The 
occurrence of receptors exhibiting low apparent affinity for 
isoproterenol and CGP-12177 in the plasma membrane frac- 
tion was a somewhat  unexpected result based  on our hypoth- 
esis that  the basis of such low affinity is sequestration of 
receptors within internalized vesicles. Therefore, the  nature 
of these receptors was investigated further. Since secondary 
lysosomes are known to migrate at a sucrose density similar 
to  that of the plasma membrane (10, 11,19, 20), we explored 
the possibility that  the low affinity receptors occurring in the 
plasma membrane fraction might be receptors that had been 
transferred from endocytotic vesicles to lysosomes. Since the 
transfer of receptors to lysosomes typically requires 10-20 
min (10, 11, 19), the proportion of receptors labeled in the 
presence of 10 p~ isoproterenol and migrating in  the plasma 
membrane fraction would be expected to increase with in- 
creasing times of desensitization. In fact, the  ratio of "plasma 
membrane" to light vesicle labeling in the presence of isopro- 
terenol was essentially constant for cells pre-exposed to iso- 





FIG. 4. Selective inhibition by CGP-12177 of labeling of 
different membrane forms  of  &adrenergic  receptors. Control 
(CTL) and desensitized (DES) cells were washed and labeled for 15 a 
with '"I-pindolol (PZm in  the absence (0) or presence (0) of 10 pM 
CGP-12177. After washing to remove '"I-pindolol not bound to 8- 
adrenergic receptors, the cells were treated with ConA and lysed, and 
the lysates were centrifuged on sucrose density gradients as described 
under "Experimental Procedures." The results shown are from a 
single experiment; similar results were obtained in one additional 
experiment. 
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receptors with [8H]CGP-12177. Control (0) and desensitized (0) 
FIG. 5. Selective labeling of plasma  membrane  @adrenergic 
cells were  waahed and incubated with 1 IIM f3H]CGP-12177 for 6 h 
on ice. After washing to remove CGP-12177 not bound to j3-adrenergic 
receptors, the cells were treated with ConA and lysed, and  the lysates 
were centrifuged on sucrose density gradients as described under 
"Experimental Procedures." The results shown are from a single 
experiment. 
proterenol for 2, 5, or 20 min (Fig. 6). This result argues 
against  a transfer of endocytotic vesicles to lysosomes as  an 
explanation for this phenomenon. 
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FIG. 6. Time  course  of  appearance  of  &adrenergic  recep- 
tors in different affinity forms assessed by  sucrose  density 
gradient  centrifugation. Cells  were incubated for 2,  5, or 20 min 
in growth medium containing isoproterenol plus ascorbate, washed, 
and  then labeled for 15 s with '"I-pindolol (PZN in the absence (0) 
or presence (0) of 10 pM isoproterenol. After washing, labeled cells 
were treated with ConA and lysed, and  the lysates were centrifuged 
on sucrose density gradients. The results shown are from a single 
experiment. 
Another test for association of these receptors with lyso- 
somes was to treat isolated fractions with a-methylmannoside 
to dissociate bound ConA and  then centrifuge the sample on 
a second sucrose density gradient. This  treatment results  in 
a shift of plasma membrane markers to a lighter sucrose 
density (20), whereas lysosomal markers  continue to sediment 
at  high sucrose densities (9, 20).  When such an experiment 
was performed with plasma membrane fractions labeled in 
the presence of 10 p~ isoproterenol (Fig. 7), the majority of 
the bound '=I-pindolol was found in  a lighter density fraction, 
suggesting that most of these receptors are associated with 
the plasma membrane and not with lysosomes. A significant 
amount of bound '261-pindolol  would be expected to dissociate 
from the receptor during the a-methylmannoside treatment 
at 37 "C; this is the most likely explanation for the low 
recovery of bound '251-pindolol and for the higher level of 
radioactivity in the first five (soluble) fractions of the second 
gradient. 
DISCUSSION 
Incubation of 1321N1 human astrocytoma cells in  the pres- 
ence of @-adrenergic receptor agonists leads to several changes 
in the @-adrenergic receptors and in coupling to adenylate 
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FIG. 7. Effect of a-methylmannoside on the sucrose density 
gradient distribution of &adrenergic receptors. Desensitized 
cells were  washed  and then labeled  for 15 s with  'Z61-pindolol (PIN) 
in the presence  of 10 ~ L M  isoproterenol.  The  amount  of  '261-pindolol 
bound in a 109-pI aliquot of each fraction was determined (first 
gradient). The remainder  of the plasma  membrane  fractions (11-14) 
were  pooled  and  treated  with  a-methylmannoside as described  under 
"Experimental  Procedures." This sample  was then centrifuged  on a 
second  sucrose density gradient. The  results  shown  are  from a  single 
experiment; similar results were obtained in a second experiment 
using  a  slightly  different  protocol. 
cyclase; these events are collectively referred to  as desensiti- 
zation (21). Two of these changes, the conversion of receptors 
to a light vesicle  form identified on  sucrose density gradients 
(BARLV) and  the conversion of receptors from a form exhib- 
iting high affinity for various hydrophilic  ligands to a form 
exhibiting low apparent affinity in short-time assays with 
intact cells (PARLA), have been postulated to result from 
internalization of BAR within endocytotic vesicles (2-8, 9). 
The experiments described  here were designed to investigate 
the relationship of these two aspects of desensitization and  to 
further define the  nature of the form(s) of the receptor exhib- 
iting these properties. 
Previous studies had shown that  the time courses  for these 
two phenomena were similar; both occur after a lag of 30-60 
s and  then proceed with a half-time of 1-2 min (2, 9). Both 
of these phenomena involve  conversion of approximately half 
of the cellular receptors to  the altered forms, and both are 
reversible with similar time courses (2,9). In addition, Fig. 1 
shows that  the formation of  DARM during exposure to isopro- 
terenol, like the formation of /3ARLv (9), is prevented if cells 
are pretreated with ConA.  However, in agreement with results 
obtained previously using assays of adenylate cyclase activity 
in membrane preparations (9),  the uncoupling of the stimu- 
lation of CAMP formation by isoproterenol is essentially 
unaltered by treatment with ConA. These results indicate 
that PARLv and PARM are formed by a common  process and 
are in fact different reflections of a single  form of the receptor. 
The results with ConA (Table 11) also support our previous 
proposal (9) that uncoupling of P-adrenergic receptors from 
stimulation of adenylate cyclase is a separate reaction that 
occurs prior to  the formation of  PARLV. 
More direct evidence in favor of this relationship between 
light vesicle receptors and low affinity receptors comes  from 
the experiment shown  in  Fig. 3. The receptors that migrate 
in the light vesicle fraction in  desensitized  cells  clearly exhibit 
low affinity for isoproterenol in short-time assays with intact 
cells; this follows since they were labeled  with  '251-pindolol  in 
the presence of a concentration of isoproterenol that blocks 
binding to high affinity but not to low affinity sites.  Although 
the results are less clear, it also appears that  the small number 
of receptors found  in the light vesicle fraction from control 
cells  includes the small population of receptors that exhibits 
low affinity for isoproterenol in short-time assays with control 
cells (Figs. 1 and 3 and Ref. 2). Thus, results from both 
control and desensitized  cells support the identity of BARLv 
and OARLA. 
While  all of the PARLv from  desensitized  cells appeared to 
exhibit low affinity for isoproterenol, some low affinity recep- 
tors also were found  in the plasma  membrane fraction. Ex- 
periments designed to  test  the hypothesis that these receptors 
were associated  with  lysosomes  (Figs. 6 and 7) proved  nega- 
tive. The shift of these labeled receptors to a lighter  sucrose 
density following treatment with a-methylmannoside pro- 
vides strong evidence that these receptors are associated  with 
the plasma membrane. If in fact the low apparent affinity 
results from receptor internalization and therefore limited 
accessibility to isoproterenol as we postulate, then  the low 
affinity receptors associated  with the plasma  membrane may 
represent an intermediate step in the internalization pathway. 
The  nature of this subpopulation of receptors is under further 
investigation. 
The recently developed P-adrenergic receptor antagonist 
CGP-12177 is a hydrophilic ligand that has been used in 
several other experimental systems to provide evidence for 
receptor internalization (15-18). In short-time assays (Fig. 3), 
this ligand distinguishes two populations of &adrenergic re- 
ceptors on intact 1321N1  cells that occur  in similar propor- 
tions to those detected by isoproterenol, epinephrine, and 
sotalol(2).  The apparent inability of CGP-12177,  even at high 
concentrations, to inhibit labeling of a small fraction of the 
receptors in control cells results from limited accessibility to 
those receptors and therefore slow equilibration. Thus, when 
equilibrium binding was  allowed to occur with various con- 
centrations of CGP-12177 prior to exposure to '251-pindolol 
(Fig. 3), all of the '251-pindolol-binding sites exhibited high 
affinity for  CGP-12177. Presumably, the same  phenomenon 
is responsible for the inability of CGP-12177 to block lZ5I- 
pindolol binding in short-time assays to the much larger 
fraction of these receptors (BARLA) in desensitized  cells. These 
results are thus similar to those previously described with 
isoproterenol and sotalol (2). In addition, the distribution of 
high and low affinity sites for  CGP-12177  between the plasma 
membrane and light vesicle fractions is essentially identical 
to that for isoproterenol (Fig. 4), suggesting that these two 
ligands are differentiating the same  forms of the receptor. 
The use of nonradioactive CGP-12177 or other hydrophilic 
antagonists in competition for  1251-pindolol binding to study 
the various  forms of the receptor is preferable to  the use of 
[3H]CGP-12177  (17, 18) for  several  reasons. First, the use of 
'251-pindolol as the radioligand  allows  labeling of all receptors 
and competition with  CGP-12177  allows the distinction, by 
selective  labeling, of low affinity receptors; thus,  the distri- 
bution of both high and low affinity receptors can be deter- 
mined using the same radioligand (Fig. 4). In contrast, the 
use  of [3H]CGP-12177 gives no information about the distri- 
bution of the low affinity receptors  (Fig. 5 and Refs.  17 and 
18). Secondly, the higher specific activity of 1251-pindolol 
makes  possible studies at short times of assay,  which  is critical 
for studying desensitized receptors in intact cells. Further- 
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more, '251-pindolol makes feasible studies in cells containing 4. Hoyer, D., Reynolds, E. E., and Molinoff, P. B. (1984) Mol. 
relatively few @-adrenergic receptors such as the 1321N1 cells Pharmacol. 25,209-218 
studied here. 5. Insel, P. A., Mahan, L.  C., Motulsky, H. J., Stoolman, L.  M., and 
The results Presented here Provide strong evidence for a 6. Chuang, D. M., and Costa, E. (1979) Proc. Natl. Acad. Sci. U. S. 
Koachman, A. M. (1983) J.  Biol. Chem. 258, 13597-13605 
direct relationship between PARL" and BARLA. These  results, A. 76,3024-3028 
together with previous studies in this (2, 8, 9) and other 7. Strulovici, B., Stadel, J. M., and Leflcowitz, R. J. (1983) J. Biol. 
experimental systems (3-7, 17, 18, 21), also provide strong Chem. 258,6410-6414 
circumstantial evidence for the localization of these forms of 8. Harden, T. K., Cotton, C. U., Waldo, G. L., Lutton, J. K., and Perkins, J. P. (1980) Science (Wash. D. C.)  210,441-443 
ther studies will no doubt proceed on the assumption that (1983) J. Biol. Chern. 258,13900-13908 
this is the case. However, definitive proof  of the intracellular 10. Brown, M. S., and Goldstein, J. L. (1979) Proc. Natl. Acad. Sci. 
location of these receptors will require direct  demonstration U. S. A. 7 6 ,  3330-3337 
using techniques such as electron microscope autoradiography 11. Pastan, L.  H., and Willingham, M.  C. (1981) Annu.  Rev.  Physiol. 
or fluorescence microscopy of @-adrenergic receptors labeled 12. Witkin, K. M., and Harden, T. K. (1981) J. Cyclic Nucleotide Res. 
with appropriate  markers.  These  studies await development 7.235-246 
the @-adrenergic receptors within endocytotic vesicles- Fur- 9. Waldo, G. L., Northup, J. K., Perkins, J. P., and Harden, T. K. 
43,239-250 
of more suitable markers for labeling of @-adrenergic receptors 
on intact cells. 
" - 
Acknowledgments-We are indebted to Sherry Jones for outstand- 
ing technical assistance and  to Angie Hodgin for her expertise in the 
preparation of the manuscript. 
REFERENCES 
1. Toews, M. L., Harden, T. K., and Perkins, J. P. (1983) Proc. 
2. Toews, M. L., and Perkins, J. P. (1984) J. Biol. Ckrn.  2 5 9 ,  
3. Pittman, R. N., and Molinoff, P. B. (1980) J. Cyclic Nucleotide 
Natl.  Acad.  Sci. U. S.  A. 80, 3553-3557 
2227-2235 
Res. 6,421-435 
13. Barovsky, K., and Brooker, G. (1980) J. Cyclic Nucleotide Res. 6, 
14. Motulsky, H. J., and Mahan, L. H. (1984) Mol. Phurmacol. 25 ,  
15. Staehelin, M., Simons, P., Jaeggi, K., and Wigger, N. (1983) J. 
16. Staehelin, M., and Simons, P. (1982) EMBO J. 1, 187-190 
17. Hertel, C., Staehelin, M., and Perkins, J. P. (1983) J. Cyclic 
18. Hertel, C., Muller, P., Portenier, M., and Staehelin, M. (1983) 
19. King, A. C., and Cuatrecasas, P. (1981) N.  Engl. J.  Med. 305, 
20. Lutton, J. K., Frederich, R. C., Jr.,  and Perkins, J. P. (1979) J. 
21. Harden, T. K. (1983) Phurrnacot. Rev. 35 ,  5-32 
297-307 
1-9 
Biol. Chern. 258,3496-3502 
Nucleotide Res. 9,119-128 
Biochem. J. 216,669-674 
77-88 
Bi01. Chem. 254,11181-11184 
